Revenio REG1V.HE
Public, HEL, reports in EUR. Founded 1999.
Theme: Medical Tech.
Medical equipment.
2025-08-01 — Hold long-term, mature
Financials millions, EUR
| Period | Revenue | Growth % | Gross margin % | R&D % | Operating income | Operating margin % | Net income | EPS (diluted) | Rule of 40 | basis |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 110m EUR | 6.0 % | 70.9 % | 1.9 % | 25m EUR | 23.2 % | 17m EUR | 0.65 | 29.1 | |
| 2024 | 104m EUR | 7.1 % | 70.4 % | 2.6 % | 26m EUR | 24.6 % | 19m EUR | 0.69 | 31.8 | |
| 2023 | 97m EUR | -0.4 % | 70.7 % | 3.0 % | 9.5m EUR | 9.8 % | 19m EUR | 0.72 | 9.4 | |
| 2022 | 97m EUR | – | 72.0 % | 3.3 % | 30m EUR | 30.6 % | 22m EUR | 0.82 | – | |
| 2026-Q2 | 39m EUR | 48.3 % | 64.6 % | – | 2.4m EUR | 6.1 % | 0.6m EUR | 0.02 | 54.4 | |
| 2026-Q1 | 27m EUR | 4.6 % | 68.5 % | – | 2.3m EUR | 8.4 % | 2.5m EUR | 0.09 | 13.0 | |
| 2025-Q4 | 31m EUR | – | 67.6 % | – | 6.7m EUR | 21.5 % | 5.5m EUR | 0.21 | – | |
| 2025-Q2 | 26m EUR | – | 72.5 % | – | 6.1m EUR | 23.0 % | 3.1m EUR | 0.12 | – | |
| 2025-Q1 | 26m EUR | – | 72.8 % | – | 6.6m EUR | 25.3 % | 4.2m EUR | 0.16 | – |
Sources
- 2025: yfinance
- 2024: 2025_10-K_Summary_2026-07-10.xlsx
- 2023: 2025_10-K_Summary_2026-07-10.xlsx
- 2022: 2025_10-K_Summary_2026-07-10.xlsx
- 2026-Q2: yfinance
- 2026-Q1: yfinance
- 2025-Q4: yfinance
- 2025-Q2: yfinance
- 2025-Q1: yfinance
Latest quarter 2026-Q2, ended 2026-06-30, vs 2025-Q2
| 2026-Q2 | 2025-Q2 | change | |
|---|---|---|---|
| Revenue | 39m EUR | 26m EUR | +13m (+48 %) |
| Op. margin | 6.1 % | 23.0 % | -16.9 pts |
| FCF | -4.2m EUR | 5.8m EUR | -10m |
| Op. income | 2.4m EUR | ||
| Net income | 0.6m EUR | ||
| EPS (diluted) | 0.02 | -82.8 % |
Cash flow millions, EUR
| Period | Cash from operations | Capex | Free cash flow | FCF margin % | CFO / net income % | NOPAT | Unlevered FCF | Levered FCF | Net change in cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | 30m EUR | 4.2m EUR | 26m EUR | 23.8 % | 173.6 % | 19m EUR | 24m EUR | 22m EUR | 8.4m EUR |
| 2024 | 24m EUR | 4.2m EUR | 20m EUR | 19.0 % | 125.0 % | 19m EUR | 21m EUR | 15m EUR | -1.1m EUR |
| 2023 | 11m EUR | 4.1m EUR | 6.8m EUR | 7.0 % | 56.8 % | 7.2m EUR | -1.6m EUR | 2.6m EUR | -10m EUR |
| 2022 | 23m EUR | 2.0m EUR | 21m EUR | 21.9 % | 106.8 % | 22m EUR | 21m EUR | 17m EUR | 6.9m EUR |
NOPAT = op. income × (1 − effective tax rate); UFCF = NOPAT + D&A + ΔNWC − capex; LFCF = FCF + net debt issued.
Quotes
| Price | 12.66 EUR | 2026-09-15 | |
|---|---|---|---|
| Market cap | 368m EUR | 425m USD | 2026-09-15 |
| 52w high | 25.85 EUR | 2026-09-15 | |
| 52w low | 11.86 EUR | 2026-09-15 | |
| EV/EBITDA | 20.0 | 2026-07-10 (stale) | |
| Off 52w high % | -51.0 % | ||
| P/S | 3.3 | ||
| Lifetime CAGR | -7.7 % |
Notes
- 2025-08-01 opinion Hold long-term, mature